Advancements and Innovative Strategies in Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cell Therapy: A Comprehensive Review.

IF 3.8 3区医学 Q2 CELL & TISSUE ENGINEERING

Stem Cells International Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI:10.1155/2024/4073485

Xiaoyu Shi, Kun Zhang, Fengshi Yu, Qi Qi, Xiaoyu Cai, Yu Zhang

{"title":"Advancements and Innovative Strategies in Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cell Therapy: A Comprehensive Review.","authors":"Xiaoyu Shi, Kun Zhang, Fengshi Yu, Qi Qi, Xiaoyu Cai, Yu Zhang","doi":"10.1155/2024/4073485","DOIUrl":null,"url":null,"abstract":"The effectiveness and safety of mesenchymal stem cell (MSC) therapy have been substantiated across various diseases. Nevertheless, challenges such as the restricted in vitro expansion capacity of tissue-derived MSCs and the clinical instability due to the high heterogeneity of isolated cells require urgent resolution. The induced pluripotent stem cell-derived MSCs (iPSC-MSCs), which is differentiated from iPSCs via specific experimental pathways, holds considerable potential as a substitute for tissue derived MSCs. Multiple studies have demonstrated that iPSCs can be differentiated into iPSC-MSCs through diverse differentiation strategies. Research suggests that iPSC-MSCs, when compared to tissue derived MSCs, exhibit superior characteristics in terms of proliferation ability, immune modulation capacity, and biological efficiency. In this review, we meticulously described and summarized the experimental methods of iPSC differentiation into iPSC-MSCs, the application of iPSC-MSCs in various disease models, the latest advancements in clinically relevant iPSC-derived cell products, and the development strategies for the next generation of iPSC-derived therapy products (not only cell products but also their derivatives).","PeriodicalId":21962,"journal":{"name":"Stem Cells International","volume":"2024 ","pages":"4073485"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458320/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cells International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/4073485","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

The effectiveness and safety of mesenchymal stem cell (MSC) therapy have been substantiated across various diseases. Nevertheless, challenges such as the restricted in vitro expansion capacity of tissue-derived MSCs and the clinical instability due to the high heterogeneity of isolated cells require urgent resolution. The induced pluripotent stem cell-derived MSCs (iPSC-MSCs), which is differentiated from iPSCs via specific experimental pathways, holds considerable potential as a substitute for tissue derived MSCs. Multiple studies have demonstrated that iPSCs can be differentiated into iPSC-MSCs through diverse differentiation strategies. Research suggests that iPSC-MSCs, when compared to tissue derived MSCs, exhibit superior characteristics in terms of proliferation ability, immune modulation capacity, and biological efficiency. In this review, we meticulously described and summarized the experimental methods of iPSC differentiation into iPSC-MSCs, the application of iPSC-MSCs in various disease models, the latest advancements in clinically relevant iPSC-derived cell products, and the development strategies for the next generation of iPSC-derived therapy products (not only cell products but also their derivatives).

查看原文本刊更多论文

诱导多能干细胞衍生间充质干细胞疗法的进展与创新策略：全面回顾。

间充质干细胞（MSC）疗法的有效性和安全性已在各种疾病中得到证实。然而，组织来源的间充质干细胞体外扩增能力受限、分离细胞的高度异质性导致临床不稳定等挑战亟待解决。诱导多能干细胞间充质干细胞（iPSC-MSCs）通过特定的实验途径从iPSCs分化而来，具有替代组织来源间充质干细胞的巨大潜力。多项研究表明，iPSC 可通过不同的分化策略分化成 iPSC-间充质干细胞。研究表明，与组织来源的间充质干细胞相比，iPSC-间充质干细胞在增殖能力、免疫调节能力和生物学效率等方面表现出更优越的特性。在这篇综述中，我们细致地描述和总结了 iPSC 分化为 iPSC-MSCs 的实验方法、iPSC-MSCs 在各种疾病模型中的应用、与临床相关的 iPSC 衍生细胞产品的最新进展以及下一代 iPSC 衍生治疗产品（不仅包括细胞产品，还包括其衍生物）的开发策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stem Cells International CELL & TISSUE ENGINEERING-

CiteScore

8.10

自引率

2.30%

发文量

188

审稿时长

18 weeks

期刊介绍： Stem Cells International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of stem cell biology and applications. The journal will consider basic, translational, and clinical research, including animal models and clinical trials. Topics covered include, but are not limited to: embryonic stem cells; induced pluripotent stem cells; tissue-specific stem cells; stem cell differentiation; genetics and epigenetics; cancer stem cells; stem cell technologies; ethical, legal, and social issues.